Immune checkpoint inhibitors in lymphoma: challenges and opportunities

Immune checkpoint inhibitors (ICIs) are immunomodulatory antibodies that intensify the host immune response, thereby leading to cytotoxicity. The primary targets for checkpoint inhibition have included cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death receptor-1 (PD-1) or p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatic, Haris, Sampat, Devi, Goyal, Gaurav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Cancer Immunotherapy: Recent Advances and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267255/
https://www.ncbi.nlm.nih.gov/pubmed/34277837
http://dx.doi.org/10.21037/atm-20-6833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267255/
https://www.ncbi.nlm.nih.gov/pubmed/34277837
http://dx.doi.org/10.21037/atm-20-6833

Ejemplares similares